The effect of insulin on circulating PCSK9 in postmenopausal obese women.
暂无分享,去创建一个
N. Seidah | R. Rabasa-Lhoret | M. Faraj | Z. Awan | R. Dufour | Alexis Baass | J. Davignon | G. Dubuc | R. Rabasa‐Lhoret | A. Baass
[1] R. Kreis,et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets , 2013, Nutrition & Metabolism.
[2] A. Peterson,et al. Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels , 2012, The Journal of Biological Chemistry.
[3] A. Prat,et al. Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice , 2012, Circulation.
[4] P. Ridker,et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. , 2012, Clinical chemistry.
[5] B. Dahlbäck,et al. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. , 2011, Atherosclerosis.
[6] R. Dullaart,et al. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients. , 2011, Atherosclerosis.
[7] Tao Yang,et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. , 2010, Atherosclerosis.
[8] J. Horton,et al. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans , 2010, Journal of Lipid Research.
[9] L. Bernier,et al. A new method for measurement of total plasma PCSK9: clinical applications , 2010, Journal of Lipid Research.
[10] E. Levy,et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. , 2009, Clinical chemistry.
[11] Jingwen Liu,et al. Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine* , 2009, The Journal of Biological Chemistry.
[12] Jonathan C. Cohen,et al. Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.
[13] B. Angelin,et al. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. , 2009, Endocrinology.
[14] E. Levy,et al. Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[15] Jonathan C. Cohen,et al. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor , 2008, Proceedings of the National Academy of Sciences.
[16] D. Lopez,et al. Diabetes alters LDL receptor and PCSK9 expression in rat liver. , 2008, Archives of biochemistry and biophysics.
[17] J. Deisenhofer,et al. Molecular basis for LDL receptor recognition by PCSK9 , 2008, Proceedings of the National Academy of Sciences.
[18] K. Cianflone,et al. Association of acylated ghrelin profiles with chronic inflammatory markers in overweight and obese postmenopausal women: a MONET study. , 2007, European journal of endocrinology.
[19] Jonathan C. Cohen,et al. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* , 2007, Journal of Biological Chemistry.
[20] Annik Prat,et al. The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR , 2007, Traffic.
[21] Leiv Ose,et al. Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[22] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[23] M. Krempf,et al. Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c* , 2006, Journal of Biological Chemistry.
[24] C. Junien,et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia , 2005, Human mutation.
[25] Alexander Pertsemlidis,et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.
[26] Jay D. Horton,et al. Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver* , 2004, Journal of Biological Chemistry.
[27] A. Prat,et al. NARC-1/PCSK9 and Its Natural Mutants , 2004, Journal of Biological Chemistry.
[28] L. Bernier,et al. Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[29] J. Breslow,et al. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] TP Leren,et al. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia , 2004, Clinical genetics.
[31] Shwu‐Yuan Wu,et al. SREBP-1c and Sp1 Interact to Regulate Transcription of the Gene for Phosphoenolpyruvate Carboxykinase (GTP) in the Liver* , 2004, Journal of Biological Chemistry.
[32] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[33] M. Skolnick,et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree , 2004, Human Genetics.
[34] Osama Hamdy,et al. Evaluation of insulin sensitivity in clinical practice and in research settings. , 2003, Nutrition reviews.
[35] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[36] S. Monier,et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. , 2003, Diabetes care.
[37] A. Prat,et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.